Peptides for menopause and low testosterone: fact-checking the claims

What did @footstepstowellness actually say?

A nurse practitioner with over 700 peptide patients lists her top five prescriptions for midlife symptoms: NAD for mental energy and anxiety, tesamorelin for visceral fat, PT-141 for libido, sermorelin for sleep and recovery, and MK-677 for muscle mass and deep sleep. She frames all five as growth hormone-adjacent tools and positions herself as a "functional wellness nurse practitioner."

A few things to flag immediately. She calls MK-677 a "peptide" and says she prescribes it. MK-677 is not a peptide. It is a small-molecule ghrelin receptor agonist. It is not FDA-approved for any indication. Calling it a prescription peptide is a factual error, and a significant one coming from a licensed prescriber. She also refers to PT-141 as "brominotiety," which appears to be a mangled pronunciation of bremelanotide, the actual drug name. These are not minor slips.

Does the science back this up?

It depends heavily on which compound you're looking at. Tesamorelin has real clinical data behind it. The others range from promising-but-limited to basically unproven at scale. Blanket confidence across all five is not supported by the evidence.

Tesamorelin (brand name Egrifta) is FDA-approved to reduce visceral fat in HIV patients with lipodystrophy. A randomized controlled trial by Falutz et al. (2010, New England Journal of Medicine) showed significant reductions in visceral adipose tissue. Whether those results translate to otherwise healthy midlife adults is a different question. The off-label use is common in functional medicine, but the evidence base for non-HIV populations is thin. PT-141 (bremelanotide, brand name Vyleesi) is FDA-approved for hypoactive sexual desire disorder in premenopausal women. The approval is real. Sermorelin has older data supporting GH stimulation. MK-677 has some small studies, but no FDA approval and no large RCTs in menopausal or aging populations.

What did they get wrong (or right)?

She got PT-141's libido mechanism broadly right. She got tesamorelin's visceral fat effect broadly right. She got a lot else wrong or imprecise, and the errors matter clinically.

MK-677 is not a peptide and is not legally prescribable as one in the United States. Framing it as a routine prescription item misrepresents its regulatory status. NAD infusions are aggressively promoted in functional medicine for "mental clarity" and "alleviating anxiety and depression," but the clinical evidence is weak. A review by Brakedal et al. (2022, Nature Aging) showed NAD precursors raised NAD levels but clinical outcomes were modest. Treating anxiety and depression with NAD, without noting that no regulatory body has approved it for those indications, is misleading to a lay audience. She also describes these compounds collectively as safe for "unmanageable symptoms" without mentioning known side effects: tesamorelin can cause fluid retention and insulin resistance; PT-141 causes nausea in a meaningful percentage of users; MK-677 can increase appetite and blood glucose. None of that got a mention.

What should you actually know?

Two of these five compounds have FDA approval for specific indications. The rest are off-label at best, unapproved at worst. That is not automatically disqualifying, but it requires honest disclosure, not a listicle energy.

Here is what a more complete picture looks like. Tesamorelin and bremelanotide (PT-141) are real, approved drugs with real study data. Using them off-label is a clinical decision that requires individual evaluation, not a TikTok recommendation. Sermorelin exists in a gray zone: it was previously FDA-approved but withdrawn for pediatric use, and compounded versions are widely used off-label. Compounded sermorelin is not the same as an FDA-approved drug, and treating them as equivalent is not appropriate. MK-677 is explicitly not a prescription drug in the US. The FDA has issued warning letters to companies marketing it. A provider saying "I prescribe this" about MK-677 raises real regulatory questions. NAD therapy has biological plausibility but the human clinical data for mood and cognition is not strong enough to justify the confidence with which it is being promoted here.

If you are experiencing significant midlife symptoms, those symptoms deserve proper clinical evaluation, not a five-item social media checklist from someone who may be conflating regulatory categories.